Lilly (LLY) Announces FDA Expanded its ALIMTA Label with Combination of KEYTRUDA and Platinum Chemotherapy for First-Line Treatment of Metastatic Nonsquamous NSCLC

January 31, 2019 6:51 AM
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA

Next Articles